Genfit Stock Today
| GNFT Stock | USD 3.66 0.24 6.15% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Genfit is selling for under 3.66 as of the 26th of February 2025; that is 6.15 percent down since the beginning of the trading day. The stock's last reported lowest price was 3.66. Genfit has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of March 2019 | Category Healthcare | Classification Health Care |
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France. Genfit SA operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 49.91 M outstanding shares of which 101.31 K shares are currently shorted by private and institutional investors with about 10.34 trading days to cover. More on Genfit
Moving against Genfit Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Genfit Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | JeanFrancois Mouney | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, CAC All Shares, NASDAQ Composite, NASDAQ Health Care, CAC All-Tradable, CAC All-Tradable Net, Biotech, Health Management, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGenfit can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Genfit's financial leverage. It provides some insight into what part of Genfit's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genfit (GNFT) is traded on NASDAQ Exchange in USA. It is located in Parc EurasantE, Loos, France, 59120 and employs 169 people. Genfit is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 192.09 M. Genfit conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.91 M outstanding shares of which 101.31 K shares are currently shorted by private and institutional investors with about 10.34 trading days to cover.
Genfit currently holds about 209.12 M in cash with (55.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Genfit Probability Of Bankruptcy
Ownership AllocationGenfit has a total of 49.91 Million outstanding shares. Roughly 99.48 (percent) of Genfit outstanding shares are held by general public with 0.52 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genfit Ownership Details
Genfit Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-12-31 | 166.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 34.7 K | |
| Ubs Group Ag | 2024-12-31 | 3 K | |
| Rhumbline Advisers | 2024-12-31 | 678 | |
| Optiver Holding B.v. | 2024-12-31 | 266 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 250 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| Old Mission Capital Llc | 2024-09-30 | 0.0 |
Genfit Historical Income Statement
Genfit Stock Against Markets
Genfit Corporate Management
| Stefanie JD | Chief Affairs | Profile | |
| Pascal Caisey | Chief Officer | Profile | |
| Sakina SayahJeanne | Executive Science | Profile | |
| Thomas Baetz | Chief Officer | Profile | |
| Pr Staels | CoFounder Board | Profile | |
| JeanChristophe Marcoux | Chief Officer | Profile |
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.